市場調查報告書

遺傳性血管水腫(HAE)- 流行病學與預測 2027年

Hereditary Angiodema - Epidemiology Forecast-2027

出版商 DelveInsight Business Research LLP 商品編碼 787158
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳性血管水腫(HAE)- 流行病學與預測 2027年 Hereditary Angiodema - Epidemiology Forecast-2027
出版日期: 2019年01月01日內容資訊: 英文
簡介

亞太地區2018年的遺傳性血管水腫(HAE)患病數推定為6萬8,813人。以患者數來看中國第1,印度第2。

這份報告提供亞太地區(中國,印度,日本,韓國,澳洲,其他的)遺傳性血管水腫(HAE)市場調查,總括性彙整市場概要,以整體及各國的市場趨勢,流行病學的預測,市場規模,患病數/診斷數的變化與預測等資訊。

目錄

第1章 遺傳性血管水腫(HAE)的患者分佈:流行病學概要

  • 整體患病數:分佈情形(實際成果值)
  • 整體患病數:分佈情形(預測值)
  • 整體診斷數:分佈情形(實際成果值)
  • 整體診斷數:分佈情形(預測值)

第2章 遺傳性血管水腫(HAE):疾病背景和概要

  • 簡介
  • 遺傳性血管水腫(HAE)的種類
    • I型及II型HAE的病理學性/免疫學性特徵
  • 臨床表現
    • 症狀
    • 相關疾病
  • 原因和風險因素
    • 潛在的誘發要素
  • 遺傳性血管水腫(HAE)的遺傳性基礎
    • 水腫形成機制
  • 遺傳性血管水腫(HAE)的診斷
    • 檢驗結果
    • 產前及出生後診斷
    • 晚開性HAE
  • 遺傳性血管水腫(HAE)的治療
    • 急性治療
    • 短期性預防
    • 長期性預防

第3章 流行病學和患者人口

  • 主要調查結果

第4章 亞太地區

  • 遺傳性血管水腫(HAE)的整體患病數
  • 遺傳性血管水腫(HAE)的整體診斷數
  • 遺傳性血管水腫(HAE)的整體診斷數:病型

第5章 遺傳性血管水腫(HAE):各國流行病學

  • 中國
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀
  • 日本
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀
  • 印度
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀
  • 韓國
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀
  • 澳洲
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀
  • 其他
    • 假設和理論的根據
    • 遺傳性血管水腫(HAE)的整體患病數
    • 遺傳性血管水腫(HAE)的診斷數
    • 遺傳性血管水腫(HAE)的診斷數:病型
    • 遺傳性血管水腫(HAE)的診斷數:性別
    • 遺傳性血管水腫(HAE)的診斷數:各年齡
    • 遺傳性血管水腫(HAE)的診斷數:不同臨床症狀

第6章 附錄

  • 報告作成方法

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0371

DelveInsight's "Hereditary Angiodema - Epidemiology Forecast-2027" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Hereditary Angiodema in the China, India, Japan, South-Korea, Australia and Rest of APAC.

Geography Covered

  • China
  • India
  • Japan
  • South-Korea
  • Australia
  • Rest of APAC

Study Period: 2016-2027

Hereditary Angiodema - Disease Understanding

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. Laryngeal edema, which may occur in 50% of patients, can cause fatal asphyxiation due to obstruction of the upper airways, and is therefore an important clinical feature of the disease. Because of its rarity-an estimated 1 in 50,000 individuals are affected (range: 1 in 10,000-1 in 150,000 worldwide) - there is often a long delay between initial onset of HAE symptoms and a formal diagnosis; misdiagnosis and medical mismanagement is not uncommon in people with the condition.

Hereditary Angioedema is characterized by sudden attacks of brawny, nonpitting edema that can cause both discomfort and pain. The swelling typically affects the extremities, genitalia, trunk, gastrointestinal tract, face, and larynx. Death by asphyxiation has been reported in 30% of patients who had laryngeal attacks in the absence of treatment. The possibility of asphyxiation from a first laryngeal attack is particularly disconcerting, especially to those patients who have family histories of HAE. Therefore, physicians as well as patients and their relatives need to develop and maintain a strong awareness of symptoms and appropriate interventions.

Hereditary Angiodema (HAE) Epidemiology

The Hereditary Angiodema (HAE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Hereditary Angiodema (HAE) are studied through all possible division to give a better understanding about the Disease scenario in APAC Countries. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hereditary Angiodema (HAE) Epidemiology Segmentation

The disease epidemiology covered in the report is segmented by total prevalent population, diagnosed-prevalent population, gender-specific prevalent population, age-specific prevalent population and type-specific prevalent population of Hereditary Angiodema.

The DelveInsight report also provides the epidemiology trends observed in the APAC Countries during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Hereditary Angiodema (HAE) was estimated to be 68,813 [APAC Countries] in 2018. Among the APAC countries, China accounts for the highest HAE cases, followed by India. Among other APAC Rest of APAC countries had the highest prevalent patient population of Hereditary Angiodema, followed by Japan.

Report Scope

  • The report covers detailed overview of Hereditary Angiodema (HAE) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the APAC Countries
  • The Report assesses the disease risk and burden and highlights the unmet needs of Hereditary Angiodema (HAE).
  • The Report helps to recognize the growth opportunities in the APAC Countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total prevalent patient population, diagnosed population, gender, age and symptom specific patient distribution in APAC Countries.

Key strengths

  • 10 Year Forecast of Hereditary Angiodema (HAE) epidemiology
  • APAC Countries Coverage
  • Total Prevalent Cases of Hereditary Angiodema (HAE)
  • Prevalent Cases according to segmentation: gender-specific prevalence, age-specific prevalence (Hereditary Angiodema)

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1 Hereditary Angioedema (HAE) Prevalent Patient Distribution (%): Epidemiology Overview at a Glance

  • 1.1 Total Prevalent Cases Distribution (%) of HAE in 2016
  • 1.2 Total Prevalent Cases Distribution (%) of HAE in 2027
  • 1.3 Total Diagnosed Prevalent Cases Distribution (%) of HAE in 2016
  • 1.4 Total Diagnosed Prevalent Cases Distribution (%) of HAE in 2027

2 Hereditary Angioedema: Disease Background and Overview

  • 2.1 Introduction
  • 2.2 Types of Hereditary Angioedema
    • 2.2.1 Pathophysiologic and Immunologic Features of Types I and II HAE
  • 2.3 Clinical Presentation
    • 2.3.1 Symptoms
    • 2.3.2 Associated diseases
  • 2.4 Causes and Risk Factors
    • 2.4.1 Potentially provoking factors
  • 2.5 Genetic Basis of Hereditary Angioedema
    • 2.5.1 Mechanisms of Edema Formation
  • 2.6 Diagnosis of Hereditary Angioedema
    • 2.6.1 Laboratory Findings
    • 2.6.2 Prenatal and Postnatal Diagnosis
    • 2.6.3 Delayed Diagnosis of HAE-A Persistent Problem with Serious Consequences
  • 2.7 Treatment of Hereditary Angioedema
    • 2.7.1 Acute therapy
    • 2.7.2 Short-term prophylaxis
    • 2.7.3 Long-term prophylaxis
  • 2.8 WAO guideline for the management of hereditary angioedema
  • 2.9 Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research
  • 2.1 Acute HAE attacks - current Australian management algorithm

3 Epidemiology and Patient Population

  • 3.1 Key Findings

4 APAC Countries

  • 4.1 Total Prevalent Population of Hereditary Angioedema in APAC Countries
  • 4.2 Total Diagnosed Prevalent Population of Hereditary Angioedema in APAC Countries
  • 4.3 Type Specific Diagnosed Prevalent Population of Hereditary Angioedema in APAC Countries

5 Country Wise-Epidemiology of Hereditary Angioedema

  • 5.1 China
    • 5.1.1 Assumptions and Rationale
    • 5.1.2 Total Prevalent Population of Hereditary Angioedema in China
    • 5.1.3 Diagnosed Prevalent Population of Hereditary Angioedema in China
    • 5.1.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China
    • 5.1.5 Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China
    • 5.1.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China
    • 5.1.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in China
  • 5.2 Japan
    • 5.2.1 Assumptions and Rationale
    • 5.2.2 Total Prevalent Population of Hereditary Angioedema in Japan
    • 5.2.3 Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 5.2.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 5.2.5 Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 5.2.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 5.2.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Japan
  • 5.3 India
    • 5.3.1 Assumptions and Rationale
    • 5.3.2 Total Prevalent Population of Hereditary Angioedema in India
    • 5.3.3 Diagnosed Prevalent Population of Hereditary Angioedema in India
    • 5.3.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India
    • 5.3.5 Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in India
    • 5.3.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India
    • 5.3.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in India
  • 5.4 South Korea
    • 5.4.1 Assumptions and Rationale
    • 5.4.2 Total Prevalent Population of Hereditary Angioedema in Korea
    • 5.4.3 Diagnosed Prevalent Population of Hereditary Angioedema in Korea
    • 5.4.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea
    • 5.4.5 Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Korea
    • 5.4.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea
    • 5.4.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in South Korea
  • 5.5 Australia
    • 5.5.1 Assumptions and Rationale
    • 5.5.2 Total Prevalent Population of Hereditary Angioedema in Australia
    • 5.5.3 Diagnosed Prevalent Population of Hereditary Angioedema in Australia
    • 5.5.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia
    • 5.5.5 Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Australia
    • 5.5.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia
    • 5.5.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Australia
  • 5.6 Rest of APAC
    • 5.6.1 Assumptions and Rationale
    • 5.6.2 Total Prevalent Population of Hereditary Angioedema in Rest of APAC
    • 5.6.3 Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC
    • 5.6.4 Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC
    • 5.6.5 Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Rest of APAC
    • 5.6.6 Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC
    • 5.6.7 Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in the Rest of APAC

6 Appendix

  • 6.1 Report Methodology

7 DelveInsight Capabilities

8 Disclaimer

9 About DelveInsight

List of Tables

  • Table 1: Total Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Table 2: Total Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Table 3: Total Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Table 4: Total Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Table 5: Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Table 6: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Table 7: Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Table 8: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Table 9: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in China (2016-2027)
  • Table 10: Total Prevalent Population of Hereditary angioedema in Japan (2016-2027)
  • Table 11: Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Table 12: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Table 13: Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Table 14: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Table 15: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Japan (2016-2027)
  • Table 16: Total Prevalent Population of Hereditary angioedema in India (2016-2027)
  • Table 17: Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Table 18: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Table 19: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in India (2016-2027)
  • Table 20: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Table 21: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in India (2016-2027)
  • Table 22: Total Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Table 23: Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Table 24: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Table 25: Sex-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Table 26: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Table 27: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in South Korea (2016-2027)
  • Table 28: Total Prevalent Population of Hereditary angioedema in Australia (2016-2027)
  • Table 29: Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Table 30: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Table 31: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Australia (2016-2027)
  • Table 32: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Table 33: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Australia (2016-2027)
  • Table 34: Total Prevalent Population of Hereditary angioedema in Rest of APAC (2016-2027)
  • Table 35: Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Table 36: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Table 37: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Rest of APAC (2016-2027)
  • Table 38: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Table 39:Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in the Rest of APAC (2016-2027)

List of Figures

  • Figure 1: C1 esterase inhibitor prevents autoactivation of complement C1
  • Figure 2: C1 esterase inhibitor inactivates factors XIIa and XIIf, plasmin, and kallikrein
  • Figure 3: C1 esterase inhibitor modulates complement and contact system activation
  • Figure 4: Risk Factors of Hereditary Angioedema
  • Figure 5: Mechanism of activation of the contact system
  • Figure 6: Diagnostic Algorithm for Hereditary Angioedema
  • Figure 7: Current clinical management algorithm for acute HAE attack
  • Figure 8: Total Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Figure 9: Total Diagnosed Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Figure 10: Total Diagnosed Prevalent Population of Hereditary Angioedema in APAC region (2016-2027)
  • Figure 11: Prevalence of Hereditary angioedema in China (2016-2027)
  • Figure 12: Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Figure 13: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Figure 14: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in China (2016-2027)
  • Figure 15: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in China (2016-2027)
  • Figure 16: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in China (2016-2027)
  • Figure 17: Prevalence of Hereditary angioedema in Japan (2016-2027)
  • Figure 18: Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Figure 19: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Figure 20: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Japan (2016-2027)
  • Figure 21: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Japan (2016-2027)
  • Figure 22: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Japan (2016-2027)
  • Figure 23: Prevalence of Hereditary angioedema in India (2016-2027)
  • Figure 24: Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Figure 25: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Figure 26: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in India (2016-2027)
  • Figure 27: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in India (2016-2027)
  • Figure 28: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in India (2016-2027)
  • Figure 29: Total Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Figure 30: Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Figure 31: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Figure 32: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in South Korea (2016-2027)
  • Figure 33: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in South Korea (2016-2027)
  • Figure 34: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in South Korea (2016-2027)
  • Figure 35: Prevalence of Hereditary angioedema in Australia (2016-2027)
  • Figure 36: Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Figure 37: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Figure 38: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Australia (2016-2027)
  • Figure 39: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Australia (2016-2027)
  • Figure 40: Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in Australia (2016-2027)
  • Figure 41: Prevalence of Hereditary angioedema in Rest of APAC (2016-2027)
  • Figure 42: Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Figure 43: Type-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Figure 44: Sex-Specific Diagnosed Prevalent Population of Hereditary angioedema in Rest of APAC (2016-2027)
  • Figure 45: Age-Specific Diagnosed Prevalent Population of Hereditary Angioedema in Rest of APAC (2016-2027)
  • Figure 46:Diagnosed Prevalent Population of Hereditary Angioedema by Clinical Manifestations in the Rest of APAC (2016-2027)
Back to Top